Business Context and Reporting Period
This Form 8-K reports the results of the 2024 Annual Meeting of Stockholders held by Tempest Therapeutics, Inc. on June 13, 2024. The filing details the voting outcomes for three proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1: Election of Directors. Stockholders elected three Class III directors to serve until the 2027 Annual Meeting.
- Stephen Brady: 7,637,500 votes for; 272,157 votes withheld.
- Michael Raab: 7,557,131 votes for; 352,526 votes withheld.
- Ronit Simantov: 7,632,144 votes for; 277,513 votes withheld.
- Proposal 2: Advisory Approval of Executive Compensation. Stockholders approved the compensation of named executive officers.
- Votes For: 7,466,910
- Votes Withheld: 167,307
- Abstentions: 275,440
- Proposal 3: Ratification of Independent Auditor. Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes For: 14,040,756
- Votes Withheld: 132,300
- Abstentions: 21,465
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares entitled to vote versus the total votes cast to assess shareholder participation rates.
- Confirm the tenure of the newly elected Class III directors (Stephen Brady, Michael Raab, Ronit Simantov) through 2027.
- Review the definitive proxy statement filed on April 23, 2024, for detailed descriptions of the executive compensation package approved in Proposal 2.
- Note the significant number of broker non-votes (6,284,864) recorded for Proposals 1 and 2, which may indicate shares held in street name where brokers lacked discretionary voting power.